Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Samsung Bioepis, which has received its first US biosimilar approval, is now set to compete with compatriot rival firm Celltrion in the US infliximab biosimilar sector, where discounting is being seen as a key factor in the uptake of these products.
Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others’ strengths, delegates at a recent conference in Seoul heard.
South Korea is mulling setting up a state-owned pharma firm as lawmakers, government officials and experts reach consensus during a recent public hearing that official intervention and control could help stabilize drug supplies and promptly deal with public health and other emergency situations.
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
South Korean clinical trial data for 2016 reflects the global boom in biologics R&D and the decline in development of synthetic drugs. A series of clinical trial failures by major South Korean pharmaceutical firms may also have weakened overall drug development activities.
South Korea is broadening its state support for the biotech industry, which it sees as a new growth engine, this time by focusing on early stage biotech start-ups, amid industry views that such support and investment in the country has so far been lacking.